• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neuroscience and Biomedical Engineering >Biomarker Research of Preclinical Alzheimer's Disease and MCI Based on Neuroimage Techniques
【24h】

Biomarker Research of Preclinical Alzheimer's Disease and MCI Based on Neuroimage Techniques

机译：基于神经影像技术的临床前阿尔茨海默氏病和MCI的生物标志物研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alzheimer's disease (AD) is an aging-related and progressive neurodegenerative disease related with age. At the time of clinical manifestation of dementia AD, significant irreversible brain damage is already present, rendering the diagnosis of AD at early stages of the disease an urgent prerequisite for therapeutic treatment to halt, or at least slow, the onset or progression of the disease progression. Recent numerous studies using the state-of-art neuroimaging techniques that have identified AD-like structural and functional brain changes in elderly people who are cognitively within the normal range or who have mild cognitive impairment (MCI), a prodromal stage of the disease are discussed. In this review, we discussed various neuroimaging measures that are proving to have potential values as biomarkers of preclinical AD pathology for the its early detection and prediction as well as serving as a clinical trial outcome measures with additional validations.
机译：阿尔茨海默氏病（AD）是与年龄相关的衰老相关的进行性神经退行性疾病。在痴呆AD的临床表现时，已经存在严重的不可逆性脑损伤，这使得在疾病的早期诊断AD成为治疗治疗以阻止或至少减慢疾病发作或进展的紧迫前提。进展。最近使用最新的神经影像学技术进行的大量研究已经确定了认知水平在正常范围内或患有轻度认知障碍（MCI）（该病的前驱阶段）的老年人的AD样结构和功能性大脑改变。讨论过。在这篇综述中，我们讨论了各种神经影像学测量方法，它们被证明具有临床前AD病理学的生物标志物的潜在价值，可用于其早期检测和预测，以及作为具有附加验证的临床试验结果指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号